The Use of NeuroAiD (MLC601)‎ in Postischemic Stroke Patients

Abstract EN

Aim.

We aimed to assess the efficacy of MLC601 on functional recovery in patients given MLC601 after an ischemic stroke.

Methods.

This is a retrospective cohort study comparing poststroke patients given open-label MLC601 (n=30; 9 female) for three months and matching patients who did not receive MLC601 from our Stroke Data Bank.

Outcome assessed was modified Rankin Scale (mRS) at three months and analyzed according to: (1) achieving a score of 0-2, (2) achieving a score of 0-1, and (3) mean change in scores from baseline.

Results.

At three months, 21 patients on MLC601 became independent as compared to 17 patients not on MLC601 (OR 1.79; 95% CI 0.62–5.2; P=0.29).

There were twice as many patients (n=16) on MLC601 who attained mRS scores similar to their prestroke state than in the non-MLC601 group (n=8) (OR 3.14; 95% CI 1.1–9.27; P=0.038).

Mean improvement in mRS from baseline was better in the MLC601 group than in the non-MLC601 group (−1.7 versus −0.9; mean difference −0.73; 95% CI −1.09 to −0.38; P<0.001).

Conclusion.

MLC601 improves functional recovery at 3 months postischemic stroke.

An ongoing large randomized control trial of MLC601 will help validate these results.